

XX Sequence 245 AA;
 SQ Query Match 94.9%; Score 1363; DB 22; Length 245;
 Best Local Similarity 99.6%; Pred. No. 1.3e-119;
 Matches 244; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 14 MTLFVLLFLVAGLLSPFANEDKDPATLTTOTQVOREYVKNHRLRAVSPRANR 73
 DB 1 MTLFVLLFLVAGLLSPFANEDKDPATLTTOTQVOREYVKNHRLRAVSPRANR 60

QY 74 LKEMNKKAANAOKMANOCNTRHSNPKDRMTSLKCGENLYMSAPSWSQAIOQWFEDEY 133
 DB 61 LKEMNKKAANAOKMANOCNTRHSNPKDRMTSLKCGENLYMSAPSWSQAIOQWFEDEY 120

QY 134 NDFDFGVGPKTPNAVYGHYTOVWYSSYLVCGNAYCPNOKVLYKYYVCOYCPAGMANR 193
 DB 121 NDFDFGVGPKTPNAVYGHYTOVWYSSYLVCGNAYCPNOKVLYKYYVCOYCPAGMANR 180

QY 194 LYPYEGGAPCASCPCDNDGGLCTNGCKYEDLYSNCKSLKLTTCCKHQLVDRSCASCNC 253
 DB 181 LYPYEGGAPCASCPCDNDGGLCTNGCKYEDLYSNCKSLKLTTCCKHQLVDRSCASCNC 240

QY 254 SNSIY 258
 DB 241 SNSIY 245

RESULT 3
 AAM24000
 ID AAM24000 standard; Protein: 245 AA.

AC AAM24000;
 DT 12-OCT-2001 (first entry)

DE Human EST encoded protein SEQ ID NO: 1525.

XX Human: sheep; pig; cow; fruit fly; yeast; hamster; macaque; horse;
 KW tomato; monkey; dog; sea urchin; expressed sequence tag; EST;
 KM diagnostics; forensic test; gene mapping; genetic disorder;
 XX biodiversity; gene therapy; nutrition.

OS Homo sapiens.
 XX MO200154477-A2.
 PN 02-AUG-2001.
 PD 25-JAN-2001; 2001MO-US02687.
 PF 25-JAN-2001; 2000US-0491404.
 PR 17-JUL-2000; 2000US-0617746.
 PR 03-AUG-2000; 2000US-0631451.
 PR 15-SEP-2000; 2000US-0663870.

XX (HYSE-) HYSEQ INC.
 PA Tang YT, Liu C, Zhou P, Qian XB, Wang Z, Chen R, Asundi V;
 PI Cao Y, Drmanac RA, Zhang J, Werhman T;
 PI WPI: 2001-476164/51.
 DR N-PSDB: AAH98659.

XX Isolated polypeptide for treatment of diseases, diagnostics, raising
 PT antibodies and research use -
 PT Claim 20: Page 1051-1052; 1275pp; English.

XX The present invention provides the protein and coding sequences of novel
 CC proteins from a variety of organisms, including human, dog, cat, horse,
 CC cow, pig, hamster, monkey, macaque, yeast, bacteria, fruit fly, sea
 CC urchin and tomato. These were derived from expressed sequence tags (ESTs)

CC from the organism of interest. They can be used in diagnostics,
 CC forensics, gene mapping, identification of mutations, to assess
 CC biodiversity and for nutritional purposes. The present sequence is a
 CC protein of the invention.

XX Sequence 245 AA;
 SQ Query Match 94.9%; Score 1363; DB 22; Length 245;
 Best Local Similarity 99.6%; Pred. No. 1.3e-119;
 Matches 244; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 14 MTLFVLLFLVAGLLSPFANEDKDPATLTTOTQVOREYVKNHRLRAVSPRANR 73
 DB 1 MTLFVLLFLVAGLLSPFANEDKDPATLTTOTQVOREYVKNHRLRAVSPRANR 60

QY 74 LKEMNKKAANAOKMANOCNTRHSNPKDRMTSLKCGENLYMSAPSWSQAIOQWFEDEY 133
 DB 61 LKEMNKKAANAOKMANOCNTRHSNPKDRMTSLKCGENLYMSAPSWSQAIOQWFEDEY 120

QY 134 NDFDFGVGPKTPNAVYGHYTOVWYSSYLVCGNAYCPNOKVLYKYYVCOYCPAGMANR 193
 DB 121 NDFDFGVGPKTPNAVYGHYTOVWYSSYLVCGNAYCPNOKVLYKYYVCOYCPAGMANR 180

QY 194 LYPYEGGAPCASCPCDNDGGLCTNGCKYEDLYSNCKSLKLTTCCKHQLVDRSCASCNC 253
 DB 181 LYPYEGGAPCASCPCDNDGGLCTNGCKYEDLYSNCKSLKLTTCCKHQLVDRSCASCNC 240

QY 254 SNSIY 258
 DB 241 SNSIY 245

RESULT 4
 ABG06656
 ID ABG06656 standard; Protein: 257 AA.

AC ABG06656;
 DT 13-FEB-2002 (first entry)

DE Novel human diagnostic protein #647.

XX Human: chromosome mapping; gene mapping; gene therapy; forensic;
 KW food supplement; medical imaging; diagnostic; genetic disorder.
 XX Homo sapiens.
 XX MO200175067-A2.
 PN 11-OCT-2001.
 PD 30-MAR-2001; 2001MO-US08631.
 PF 31-MAR-2000; 2000US-0540217.
 PR 23-AUG-2000; 2000US-0649167.

XX (HYSE-) HYSEQ INC.
 PA Drmanac RT, Liu C, Tang YT;
 PI WPI: 2001-639362/73.
 DR N-PSDB: AAS70843.

XX New isolated polynucleotide and encoded polypeptides, useful in
 PT diagnostics, forensics, gene mapping, identification of mutations
 PT responsible for genetic disorders or other traits and to assess
 PT biodiversity -
 PT Claim 20: SEQ ID NO 37015; 103pp; English.

XX The invention relates to isolated polynucleotide (I) and
 CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome

CC and gene mapping, and in recombinant production of (II). The
 CC polynucleotides are also used in diagnostics as expressed sequence tags
 CC for identifying expressed genes. (I) is useful in gene therapy techniques
 CC to restore normal activity of (II) or to treat disease states involving
 CC (II). (II) is useful for generating antibodies against it, detecting or
 CC quantitating a polypeptide in tissue, as molecular weight markers and as
 CC a food supplement. (II) and its binding partners are useful in medical
 CC imaging of sites expressing (II). (I) and (II) are useful for treating
 CC disorders involving aberrant protein expression or biological activity.
 CC The polypeptide and polynucleotide sequences have applications in
 CC diagnostics, forensics, gene mapping, identification of mutations
 CC responsible for genetic disorders or other traits to assess biodiversity
 CC and to produce other types of data and products dependent on DNA and
 CC amino acid sequences. ABG00010-ABG30377 represent novel human
 CC diagnostic amino acid sequences of the invention.
 CC Note: The sequence data for this patent did not appear in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pcl_sequences.

SO Sequence 257 AA:

Query Match 69.1%; Score 992; DB 22; Length 257;
 Best Local Similarity 72.0%; Pred. No. 8.8e-85;
 Matches 177; Conservative 25; Mismatches 42; Indels 2; Gaps 2;

OY 13 MTLFVLLFLVAGLLPSFPANEDKPAFTALLTTOYOVREIVKHNELRAVSPARN 72
 DB 14 MALLPV-LFLVTVLLPSLPA-EGKDPFTALLTLOQVREIVKHNELRAVSPARN 71
 OY 73 MKEMKREAAANAKNOCNRYHSNPKDMTSLKCGENLYMSAPSSMSQAIOSEFDE 132
 DB 72 MKEMKREVTTNQKMANCKTLOHSDPEDKSTKCGENLYMSAPSSMSQAIOSEFDE 131
 OY 133 VNDEFGVGRKTPNAVYGHYTOVWYSSYLVCAGNACPNQKYLKYRYVCOYCPAGNMAN 192
 DB 132 LIDFVYGVGRSPNAVYGHYTOVWYSSYLVCAGNACPNQKYLKYRYVCOYCPAGNMAN 191
 OY 193 RLYVVEGACAPCASPNDGDLCTNGCKYEDLYSNCKSLKTLTKHQHQLVRDSCAKSCN 252
 DB 192 RNFYVQGGPCACGCDPCDKGLCTNSCOYDILLNSDLSKNTACGHEHLLKCKKATCGL 251
 OY 253 GSNISY 258
 DB 252 CENKTY 257

RESULT 5
 ID AAE13072 standard; Protein: 243 AA.

AC AAE13072;
 DT 28-JAN-2002 (first entry)
 DE Homo sapiens (Hs)-TpX protein.

XX
 OS Homo sapiens.
 FH Key
 FT Peptide 1..22 Location/Qualifiers
 FT /label= Signal_peptide
 FT Protein 23..243
 FT /label= Mature_Hs-TpX_protein
 XX

PN M0200174385-A1.
 XX
 PD 11-OCT-2001.
 XX
 PF 27-MAR-2001; 2001WO-US09798.
 PR
 XX 03-APR-2000; 2000US-0541759.
 PA (NYBL-) NEW YORK BLOOD CENT INC.
 PA (UYCA-) UNIV CASE WESTERN RESERVE.
 PA (UABR-) UAB RES FOUND.
 PI Lustigman S, Pearlman E, Unasch TR:
 XX WPI; 2001-662950/76.
 DR
 XX
 PT Inducing angiogenesis in a tissue using the Ov-ASP protein isolated
 PT from the nematode *Onchocerca volvulus* is useful to treat circulatory or
 PT vascular disease such as ischemia.

Disclosure: Fig 1; 37pp; English.

The present invention relates to a method for inducing angiogenesis in a
 CC tissue. The method comprising contacting the tissue with Ov-ASP. The Ov-
 CC ASP molecules are used to treat circulatory or vascular disorders,
 CC particularly ischemia, congenital heart disease, myocardial disease or
 CC pericardial disease, more particularly cerebrovascular ischemia, veno-
 CC clusive disease or myocardial ischemia, especially coronary artery
 CC disease. The invention is also used to treat cancer, diabetic
 CC retinopathy and inflammatory disease. Angiogenesis is also central to a
 CC number of pathological processes, including abnormalities of wound
 CC healing in diseases such as diabetes and duodenal ulceration; chronic
 CC inflammatory disorders such as rheumatoid arthritis, psoriasis and
 CC Kaposi's sarcoma; pyogenic granulomas and warts. Anti-Ov-ASP factors are
 CC useful to treat onchocerciasis (River Blindness) or benign or malignant
 CC neoplasia. The present sequence is homo sapiens (Hs)-TpX protein.

SO Sequence 243 AA:

Query Match 68.7%; Score 986; DB 22; Length 243;
 Best Local Similarity 71.4%; Pred. No. 3e-84;
 Matches 175; Conservative 26; Mismatches 42; Indels 2; Gaps 2;

OY 14 MTLFVLLFLVAGLLPSFPANEDKPAFTALLTTOYOVREIVKHNELRAVSPARNM 73
 DB 1 MALLPV-LFLVTVLLPSLPA-EGKDPFTALLTLOQVREIVKHNELRAVSPARNM 58
 OY 74 LKEMKREAAANAKNOCNRYHSNPKDMTSLKCGENLYMSAPSSMSQAIOSEFDEY 133
 DB 59 LKEMKREVTTNQKMANCKTLOHSDPEDKSTKCGENLYMSAPSSMSQAIOSEFDEY 118
 OY 134 NQDFEFGVGRKTPNAVYGHYTOVWYSSYLVCAGNACPNQKYLKYRYVCOYCPAGNMANR 193
 DB 119 LDFVYGVGRSPNAVYGHYTOVWYSSYLVCAGNACPNQKYLKYRYVCOYCPAGNMANNR 178
 OY 194 RLYVVEGACAPCASPNDGDLCTNGCKYEDLYSNCKSLKTLTKHQHQLVRDSCAKSCN 253
 DB 179 RNFYVQGGPCACGCDPCDKGLCTNSCOYDILLNSDLSKNTACGHEHLLKCKKATCGL 248
 OY 254 GSNISY 258
 DB 239 ENKTY 243

RESULT 6
 ID AAY44013 standard; Protein: 138 AA.

AC AAY44013;
 DT 21-DEC-1999 (first entry)
 XX

DE Human testis specific protein #2.
 XX Prediction: secondary structure; alignment; evolutionary conservation;
 KW homology; periodicity; co-variation analysis; antigenic site;
 KW site directed mutagenesis; interaction.
 XX
 OS Homo sapiens.
 XX
 PN US958784-A.
 XX
 PD 28-SEP-1999.
 XX
 PF 25-MAR-1992; 9205-0857224.
 XX
 PR 25-MAR-1992; 9205-0857224.
 XX
 PA (BENN/) BENNER S A.
 XX
 PI Benner SA;
 XX
 DR WPI; 1999-570766/48.
 XX
 PT Predicting the folded structure of proteins -
 PS
 XX disclosure: Column 389-390; 113pp: English.
 XX
 CC Sequences AY43902-Y44015 represent proteins used in a novel method of
 CC predicting the folded structure of proteins, by aligning sequences of
 CC homologous proteins and using patterns of evolutionarily conserved and
 CC varied sequences to assign positions. Positions in the alignment are
 CC assigned to the surface or inside of the folded structure, active sites,
 CC and parsing segments. Secondary structural units are assigned by
 CC identifying periodicity in the assignments, and assembled into globular
 CC form using distance constraints imposed by disulfide bridges, active
 CC site assignments and co-variation analysis. The predicted secondary
 CC structures are useful for identifying antigenic sites on a protein
 CC molecule, as guides for site directed mutagenesis studies, and for
 CC understanding the interaction of a protein with other molecules.
 XX
 SQ Sequence 138 AA;
 Query Match 41.4%; Score 595; DB 20; Length 138;
 Best Local Similarity 71.7%; Pred. No. 6,7e-48;
 Matches 99; Conservative 16; Mismatches 23; Indels 0; Gaps 0;
 QY 74 LKMKENKKAANAOXKMANOCNRYHNSPKDRMTSLKCGENLYMSSAASSSQAIQSPNDEY 133
 DB 1 LKMKENKKAANAOXKMANOCNRYHNSPKDRMTSLKCGENLYMSSAASSSQAIQSPNDEY 60
 QY 134 NDFDEGVGPKTPNNAVGHYTVVWYSSYLVCGNAYCPNOKVLKYYVCOYCPAGNMNR 193
 DB 61 LDFVYGVGPKSPNNAVGHYTVVWYSSYLVCGNAYCPNOKVLKYYVCOYCPAGNMNR 120
 QY 194 LYPVEGAGPCASCPCDNC 211
 DB 121 KNTPTVOGGTPCAGCPDNC 138
 RESULT 7
 ABG06655
 ID ABG06655 standard; Protein: 168 AA.
 AC ABG06655;
 XX
 DT 13-FEB-2002 (first entry)
 XX
 DE Novel human diagnostic protein #6646.
 XX
 KW Human: chromosome mapping; gene mapping; gene therapy; forensic;
 KW food supplement; medical imaging; diagnostic; genetic disorder.
 XX
 OS Homo sapiens.
 XX

PN W0200175067-A2.
 XX
 PD 11-OCT-2001.
 XX
 PF 30-MAR-2001; 2001WO-US08631.
 XX
 PR 31-MAR-2000; 2000US-0540217.
 XX
 PR 23-AUG-2000; 2000US-0649167.
 XX
 PA (HYSE-) HYSEQ INC.
 XX
 PI Drmanac RT, Liu C, Tang YT;
 XX
 DR WPI; 2001-639362/73.
 XX
 DR N-PSDB; NAST0842.
 XX
 PT New isolated polynucleotide and encoded polypeptides, useful in
 PT diagnostics, forensics, gene mapping, identification of mutations
 PT responsible for genetic disorders or other traits and to assess
 PT biodiversity
 XX
 PS Claim 20: SEQ ID NO 37014; 103pp: English.
 XX
 CC The invention relates to isolated polynucleotide (I) and
 CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
 CC and gene mapping, and in recombinant production of (II). The
 CC polynucleotides are also used in diagnostics as expressed sequence tags
 CC for identifying expressed genes. (I) is useful in gene therapy techniques
 CC to restore normal activity of (II) or to treat disease states involving
 CC (II). (II) is useful for generating antibodies against it, detecting or
 CC quantifying a polypeptide in tissue, as molecular weight markers and as
 CC a food supplement. (II) and its binding partners are useful in medical
 CC imaging of sites expressing (II). (I) and (II) are useful for creating
 CC disorders involving aberrant protein expression or biological activity.
 CC The polypeptide and polynucleotide sequences have applications in
 CC diagnostics, forensics, gene mapping, identification of mutations
 CC responsible for genetic disorders or other traits to assess biodiversity
 CC and to produce other types of data and products dependent on DNA and
 CC amino acid sequences. ABG00010-ABG30377 represent novel human
 CC diagnostic amino acid sequences of the invention.
 CC Note: The sequence data for this patent did not appear in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp://ipo.int/pub/published_pct_sequences.
 XX
 SQ Sequence 168 AA;
 Query Match 39.9%; Score 572.5; DB 22; Length 168;
 Best Local Similarity 58.9%; Pred. No. 1.1e-45;
 Matches 113; Conservative 14; Mismatches 26; Indels 39; Gaps 3;
 QY 13 AMTFLPVLLFLVAGLPSFPAEDKDPFALLTTOTVOREIVKNEELRAVSPRAN 72
 DB 14 AMALLPV-LEFLVYVLLPSLPA-EGKDPAPFALLTTOTVOREIVKNEELRAVSPRAN 71
 QY 73 LKMKENKKAANAOXKMANOCNRYHNSPKDRMTSLKCGENLYMSSAASSSQAIQSPNDEY 132
 DB 72 LKMKENKKAANAOXKMANOCNRYHNSPKDRMTSLKCGENLYMSSAASSSQAIQSPNDEY 131
 QY 133 YNDFDEGVGPKTPNNAVGHYTVVWYSSYLVCGNAYCPNOKVLKYYVCOYCPAGNMNR 192
 DB 132 ILDFVYGVGPKSP-----OYCPAGNMNR 154
 QY 193 RLYVPEGAGPC 204
 DB 155 RKNTPVOGGTPC 166
 RESULT 8
 AA44012
 ID AA44012 standard; Protein: 137 AA.
 AC AA44012;
 XX

XX	21-DEC-1999	(first entry)	
XX	Human testis specific protein #1.		
DE	Prediction: secondary structure; alignment; evolutionary conservation;		
KW	homology; periodicity; co-variation analysis; antigenic site;		
KW	site directed mutagenesis; interaction.		
XX			
OS	Homo sapiens.		
XX			
PN	U55958784-A.		
XX			
PD	28-SEP-1999.		
XX			
PF	25-MAR-1992: 92US-0857224.		
XX			
PR	25-MAR-1992: 92US-0857224.		
XX			
PA	(BENN/) BENNER S. A.		
XX			
PI	Benner SA;		
XX			
DR	WPI: 1999-570766/48.		
XX			
PT	Predicting the folded structure of proteins		
XX			
PS	Disclosure: Column 387-388; 113pp; English.		
XX			
CC	Sequences AAY43902-Y44015 represent proteins used in a novel method of		
CC	predicting the folded structure of proteins, by aligning sequences of		
CC	homologous proteins and using patterns of evolutionarily conserved and		
CC	varied sequences to assign positions. Positions in the alignment are		
CC	assigned to the surface or inside of the folded structure, active sites,		
CC	and pairing segments. Secondary structural units are assigned by		
CC	identifying periodicity in the assignments, and assembled into globular		
CC	form using distance constraints imposed by disulfide bridges, active		
CC	site assignments and co-variation analysis. The predicted secondary		
CC	structures are useful for identifying antigenic sites on a protein		
CC	molecule, as guides for site directed mutagenesis studies, and for		
CC	understanding the interaction of a protein with other molecules.		
XX			
XX	Sequence 137 AA;		
QY	Query Match 35.3%; Score 507.5; DB 20; Length 137;		
	Best Local Similarity 61.6%; Pred. No. 1,1e-39;		
	Matches 85; Conservative 20; Mismatches 32; Indels 1; Gaps 1;		
QY	74 LKEMNKKAANPAOKMKNOCNRYSHSPKDRMTSLKCGENTLYNSSAPSSMSOAISWFDY 133		
DB	1 LKEMNSIQTTNNAOKMANKCILEHSSKXDRKINRCGENIMYTDPTLMSYIOSMTNEN 60		
QY	134 NDDDEYVGKTPNMAVGHYQVYVWYSSTLYCGNANCPNOKYLYKTYVCGYCPAGNMANR 193		
DB	61 EDVYIVGVGAK-PNSAVGHITOLWMISSFRIIGGATGCPNODNLKTYVCHTCPMGNVMK 119		
QY	194 LYPIYEQACAPCASPDC 211		
DB	120 KSTPIYQGGTPCASCPCNMC 137		
RESULT 9			
AAAY44011			
AAAY44011	standard; Protein; 137 AA.		
AAAY44011:			
21-DEC-1999	(first entry)		
Rat sperm coating glycoprotein.			
Prediction: secondary structure; alignment; evolutionary conservation;			
homology; periodicity; co-variation analysis; antigenic site;			

KW	site directed mutagenesis; interaction.
XX	
OS	Bos taurus.
PN	US5958784-A.
PD	28-SEP-1999.
PF	25-MAR-1992;
PR	25-MAR-1992; 92U5-085722A.
PA	(BENN/) BENNER S A.
PI	Benner SA;
DZ	WPt: 1999-570766/48.
PT	Predicting the folded structure of proteins -
PS	Disclosure: Column 385-388; 11pp: English.
CC	Sequences AAIV3902-Y44015 represent proteins used in a novel method of predicting the folded structure of proteins, by aligning sequences of homologous proteins and assigning positions of evolutionarily conserved amino acid residues to assign positions. Positions in the alignment are assigned to the surface or inside of the folded structure, active sites, disulfide bridges, and pairing segments. Secondary structural units are assigned by identifying periodicity in the assignments, and assembled into globular forms using distance constraints imposed by disulfide bridges, active site assignments and co-variance analysis. The predicted secondary structures are useful for identifying antigenic sites on a protein molecule, as guides for site directed mutagenesis studies, and for understanding the interaction of a protein with other molecules.
SQ	Sequence 137 AA:
OY	Query Match 33.8%; Score 485.5; DB 20; Length 137; Best Local Similarity 60.1%; Pred. No. 1.2e-17; Matches 83; Conservative 18; Mismatches 36; Indels 1; Gaps 1;
DB	1 LKEMNKREAAANAKMANOCNYRHSPDKDRMTSLKCENLYMSSAPSWGAIQSWEDEY 133 : : : : : : : : : : : : : : : : I LRVENHDADVYNNAOKMANRCIYNHNSPLQRHTTTLKGCEINLFMANYPASMSVIIDPWDES 60
OY	134 NDDPEFCVGKPKNADVGHYYGVVWSYLVCGNAYCPDNCKVLKYTYVCOYCPCAGNNAMR 193 61 LDVPFGCGKKVKYGKVGHGYOVVMNSTFLYACGAVECDPP-LKRYTVCHCPCPGNVGR 119
OY	194 LVLPYEQGAPCASCPDNC 211 : : 120 LYSPIIEGEPCDCPQC 137
ID	AAYII1989 standard; Protein: 71 AA. AAYII1989
AC	AAYII1989;
DT	18-JUN-1999 (first entry)
DE	Human 5' EST secreted protein SEQ ID NO: 589.
KW	Human: secreted protein; EST: expressed sequence tag; diagnosis: forensic: gene therapy; chromosome mapping; signal peptide; prostate; upstream regulatory sequence; cytokine activity; cell proliferation; differentiation; hematopoiesis regulation; tissue growth regulation; reproductive hormone regulation; chemotactic; chemokinetic; hemostatic; chronolytic; anti-inflammatory; tumour inhibition.
HX	Homo sapiens.

PN W09906550-A2.
 XX 11-FEB-1999.
 XX 31-JUL-1998; 96W0-1801232.
 XX 01-AUG-1997; 97US-0905144.
 XX (GEST) GENSET.
 PI Ductect A, Dumas Milne Edwards J, Lacroix B;
 DR WPI: 1999-153780/13.
 DR N-PSDB: AAX40711.
 XX New isolated prostate-derived nucleic acids - used to develop
 PT products which may have cytokine, immune regulatory, haematopoiesis
 PT regulating, anti-inflammatory or tumour inhibition activity
 XX
 PS Claim 34; Page 672; 675pp: English.
 XX AAX40438 to AAX40715 represent 5' expressed sequence tags (ESTs) for
 CC human secreted proteins expressed in prostate, and encode the proteins
 CC given in AAX11716 to AAX11993 respectively. The proteins given represent
 CC the signal peptide and an N-terminal fragment of a secreted protein. The
 CC nucleic acid sequences can be used for producing secreted human gene
 CC products. They can also be used to develop products for diagnosis and
 CC therapy. The proteins obtained may have cytokine activity, cell
 CC proliferation and differentiation activity, haematopoiesis regulating
 CC activity, tissue growth regulating activity, reproductive hormone
 CC regulating activity, chemotactic/chemokinetic activity, haemostatic and
 CC thrombolytic activity, receptor/ligand activity, anti-inflammatory
 CC activity, tumour inhibition activity or other activities. The products
 CC can be used in forensic, gene therapy and chromosome mapping procedures.
 CC The sequences can also be used for obtaining corresponding promoter.
 CC sequences. The nucleic acids encoding the signal peptides can be used for
 CC directing extracellular secretion of a polypeptide or the insertion of a
 CC polypeptide into a membrane, or importing a polypeptide into a cell.
 XX
 SQ Sequence 71 AA:
 Query Match 24.7%; Score 354; DB 20; Length 71;
 Best Local Similarity 98.6%; Pred. No. 1.1e-25;
 Matches 70; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 OY 1 MCOLHPALLETMTLPVLLFVAGLSPSPANEDKDPATALLTOTOVOREIVNKN 60
 DB 1 MCOLHPALLETMTLPVLLFVAGLSPSPANEDKDPATALLTOTOVOREIVNKN 60
 OY 61 ELRRAVSPPAR 71
 DB 61 ELRRAVSPPAR 71
 RESULT 11
 AAE18962
 ID AAE18962 standard; Protein: 255 AA.
 AC AAE18962;
 XX 21-MAR-2002 (first entry)
 DE Mouse testes-specific, vespid and pathogenic protein (RTVP).
 XX Mouse: testes-specific, vespid and pathogenic protein (RTVP); therapy;
 KW anti-neoplastic; prostatic neoplasia; prostate carcinoma; cytokine;
 KM metastatic disease; neoplastic disease; immune system; growth factor;
 KM cytosolic.
 XX
 OS Mus sp.
 XX
 FT key Location/Qualifiers
 FT Peptide 1..16

FT Protein /label= Signal_peptide
 FT 17..255 /note= "Mouse mature RTVP protein"
 FT Modified-site 90..92 /note= "N-glycosylation site"
 FT Domain 135..144 /note= "Extracellular protein signature motif 1"
 FT Domain 160..170 /note= "Extracellular protein signature motif 2"
 FT Misc-difference 195 /note= "Encoded by TG"
 FT Misc-difference 210 /note= "Encoded by GCAR"
 FT Domain 222..244 /note= "Transmembrane domain"
 FT W0200206344-A2.
 PD 24-JAN-2002.
 PE 08-JUN-2001; 2001HO-US18487.
 PR 08-JUN-2000; 2000US-209989P.
 PA (BAYU) BAYLOR COLLEGE MEDICINE.
 PI Thompson TC, Ren C;
 XX WPI: 2002-195804/25.
 DR N-PSDB: AAD30356.
 XX Novel testes-specific, vespid and pathogenic polypeptide useful for
 PT treating and preventing prostatic neoplastic diseases, such as
 PT prostatic carcinoma and metastatic carcinoma, has antineoplastic
 PT activity
 XX
 PS Claim 22; Fig 1B; 72pp: English.
 XX
 CC The invention relates to a gene encoding non-human testes-specific,
 CC vespid and pathogenic protein (RTVP) having anti-neoplastic activity.
 CC The invention further relates to compositions and methods based on RTVP
 CC for the treatment, prevention and detection of prostatic neoplasia such
 CC as prostatic carcinoma and associated metastatic disease. Diagnostic kit
 CC comprising RTVP protein is useful for the detection of neoplastic
 CC disease. Composition comprising RTVP protein is useful in the diagnosis,
 CC studying and treatment of prostatic neoplasia such as prostatic carcinoma
 CC and associated metastatic disease. It is also useful for stimulating
 CC immune system e.g. cytokines and growth factors in a patient. The present
 CC sequence is mouse RTVP protein.
 XX
 SQ Sequence 255 AA:
 Query Match 24.0%; Score 344; DB 23; Length 255;
 Best Local Similarity 33.6%; Pred. No. 5.3e-24;
 Matches 88; Conservative 37; Mismatches 81; Indels 56; Gaps 12;
 OY 19 VILFLVAGLSPSPANEDKDPATALL--TTOTOVOREIVNHNELRRAVSPPARMLK 75
 DB 3 VILAVIVMASSVSS-----STASTLPDITNEDFIKEOVYHNDLRKSVSPARMLK 57
 OY 76 MERNKEAANAKNANOCNRRHSNPK-----DRNTSICKGEMLYMS--APSSMSOAIOS 128
 DB 58 MSWDPLAQIAAATKSCFEKH-NPDLHSRIHPNTAL--GENIWMGSLSIFSVSALSA 114
 OY 129 WPEDEYDFPGVGRPTNNAVYHTOVVWYSSYLVCGMAYCPNOVLKYYVVCQYCPAG 188
 DB 115 WYEIEIKHYDFSR--RKCRHVCGHYTOVWADSKYKGCAYVQCPNGA---NFCIDYGPAG 168
 OY 189 NMANRLYVYEGGAPCASC--DNCDDGLCTN-----GCKYEDL 225
 DB 169 NPT---WPIKOGATSCCPKDRDKLNSLCINPRDOVSRTYSVDYPPMPTILNRRTISL 225
 OY 226 YSNCKSLKL-----TILCKHQ 241

DB 226 FLIAKSVLLSLVITIKWKH 247

RESULT 12

ID AAB01400 standard. Protein: 219 AA.

XX AAB01400:

AC 20-OCT-2000 (first entry)

XX Neuron-associated protein.

DE Neuron-associated protein.

XX Neuron-associated protein: NEUAP; neurological disorder; epilepsy;

KM Ischemic cerebrovascular disease; stroke; cerebral neoplasm;

KM Alzheimer's disease; Pick's disease; Huntington's disease;

KM dementia; Parkinson's disease; demyelinating disease; meningitis;

KM prion disease; Kuru; Creutzfeldt-Jakob disease; neurofibromatosis;

KM cerebral palsy; muscular dystrophy; central nervous system; CNS;

KM peripheral nervous system; PNS; myopathy; schizophrenia;

KM actinic keratosis; arteriosclerosis; atherosclerosis; buritis;

KM cirrhosis; hepatitis; mixed connective tissue disease; MCTD;

KM myelofibrosis; paroxysmal nocturnal haemoglobinuria; cancer;

KM autoimmune disease; inflammation; acquired immunodeficiency syndrome;

KM AIDS; Addison's disease; adult respiratory distress syndrome;

KM allergy; ankylosing spondylitis; amyloidosis; anaemia; asthma;

XX Werner syndrome; trauma; human.

OS Homo sapiens.

XX WO200034477-A2.

XX 15-JUN-2000.

PD 10-DEC-1999; 99MO-US30408.

XX 11-DEC-1998; 98US-0210083.

PR 11-DEC-1998; 98US-9123456.

PR 09-FEB-1999; 99US-0119365.

PR 16-MAR-1999; 99US-0124687.

XX (INCYTE PHARM INC.

PA Tang YT, Yue H, Baughn MR, Hillman JL, Lal P, Au-Young J, Yang J;

PI Lu DM, Azimzai Y;

XX WPI: 2000-423423/36.

DR New human neuron-associated proteins and polynucleotides encoding them,

XX useful for diagnosis, treatment and prevention of cell proliferative

PT disorders including cancer, neuronal and neurological disorders

XX Disclosure: Page 144-145; 14pp; English.

PS Human neuron-associated proteins (NEUAP) can be used for for

XX treating or preventing a disorder associated with decreased

CC expression or activity of NEUAP. Antagonists of NEUAP are useful for

CC treating or preventing disorder associated with increased expression

CC or activity of NEUAP. NEUAP or their fragments or derivatives are

CC useful for treating neurological disorder such as epilepsy, ischemic

CC cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's

CC disease, Pick's disease, Huntington's disease, dementia and

CC Parkinson's disease. NEUAPs are also useful for treating other

CC demyelinating diseases, bacterial and viral meningitis, prion

CC diseases including Kuru, Creutzfeldt-Jakob disease, nutritional and

CC metabolic diseases of the nervous system, neurofibromatosis, other

CC developmental disorders of the central nervous system, cerebral

CC palsy, neuroskeletal disorders, autonomic nervous system disorders,

CC cranial nerve disorders, spinal cord diseases, muscular dystrophy and

CC other neuromuscular disorders, peripheral nervous system disorders,

CC inherited, metabolic, endocrine, and toxic myopathies, mental

CC disorders including mood, anxiety and schizophrenic disorders, a cell

CC proliferative disorder such as actinic keratosis, arteriosclerosis,

CC atherosclerosis, buritis, cirrhosis, hepatitis, mixed connective

CC tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal

CC haemoglobinuria, cancers of the adrenal gland, bladder, bone,

CC bone marrow, brain, breast, cervix, and an autoimmune/inflammatory

CC disorder such as acquired immunodeficiency syndrome (AIDS), Addison's

CC disease, adult respiratory distress syndrome, allergies, ankylosing

CC spondylitis, amyloidosis, anemia, asthma, Werner syndrome,

CC complications of cancer, hemodialysis, and extracorporeal circulation,

CC viral, bacterial, fungal parasitic, protozoal, and helminthic

CC infections, and trauma. This protein was designated 9847722.

XX Sequence 219 AA:

SO

Query Match 22.5%; Score 322.5; DB 21; Length 219;

Best Local Similarity 36.5%; Pred. No. 4; se 22;

Matches 77; Conservative 30; Mismatches 63; Indels 41; Gaps 11;

QY 25 AGLESPPANEDKDPATALLTQOVOREIVYKHNELRRVSPARKMLKMNKEEAA 84

DB 12 ANILPDI-ENED-----FIKDCVRHNKFRSEVPTASDMLTYTDPALAQ 56

QY 85 NQKMANCNCYRHS---NPKDRK---TSLKCGENTLYSSAP--SSWSQAIOSMFDEYND 136

DB 57 IKAANASNCPSNTRAKPRKHHPFTSL--GENITGVSPIFVSASATNWTDELDY 114

QY 137 DRGVGPKTPNAVGHYQYVWMSYLVGCGNAYCPNOKULKY-----YYVCOYCPAGN 189

DB 115 NFRT--RICKRVCGHYQVWMSDYKVGCAVOFCP--KVSFDALSGAHFTCNVGGGN 170

QY 190 WANRLVPEEQAPCASCBDN--CDGGLCTN 218

DB 171 YPT---WPKRGATCSACPNDKCDNLNVN 198

RESULT 13

ID AAB43408 standard; Protein: 302 AA.

XX AAB43408:

XX 08-FEB-2001 (first entry)

XX Human cancer associated protein sequence SEQ ID NO:853.

DE Human: cancer associated gene; cancer antigen; detection; cancer;

KM diagnosis; cytostatic; proliferative; vulnery; immunomodulator;

KM antidiabetic; antistatic; antirheumatic; antihypertic; antiviral;

KM antiinflammatory; antithyroid; antileptoric; antibacterial; cardiac;

KM dermatological; neuroprotective; thrombolytic; coagulant; noctropic;

KM vasotropic; antipsoritic; antidiabetic; gene therapy; inflammation;

KM immune disorder; hematopoietic cell disorder; autoimmune disorder;

KM allergic reaction; graft versus host disease; organ rejection;

KM haemostatic; thrombolytic; cardiovascular disorder; infection;

XX neurological disease; drug screening.

XX Homo sapiens.

OS WO200055350-A1.

XX 21-SEP-2000.

PD 08-MAR-2000; 2000MO-US05682.

XX 12-MAR-1999; 99US-0124270.

PR (HUMA-) HUMAN GENOME SCI INC.

PA Rosen CA, Ruben SM;

PI WPI: 2000-587533/55.

DR N-PSDB: AAC77617.

PT Novel isolated nucleic acids comprising sequences encoding peptides
 useful for treating or diagnosing e.g. cancer -
 PS Claim 11; Page 1406-1407; 2352pp; English.
 CC AAC7607 to AAC7844 encode the human cancer associated proteins given
 CC in AAB43398 to AAB44239. The proteins can have activities based on the
 CC tissues and cells the genes are expressed in. Example of activities
 CC include: cytostatic; proliferative; antiangiogenic; anti-invasive;
 CC antidiabetic; antihypertensive; antiallergic; antineoplastic; antiinflammatory;
 CC dermatological; neuroprotective; cardiant; thrombolytic; coagulant;
 CC neoplastic; vasotropic; antiparasitic and antiparasitic. The
 CC polynucleotides and polypeptides can be used for preventing, treating or
 CC ameliorating medical conditions and diagnosing pathological conditions.
 CC Polynucleotides, antibodies, agonists, antagonists and antagonists from
 CC the present invention may be used to treat immune disorders by activating
 CC or inhibiting the proliferation, differentiation or mobilisation of
 CC immune cells, to treat disorders of haematopoietic cells, autoimmune
 CC disorders, allergic reactions, graft versus host disease and organ
 CC rejection, modulate haemostatic or thrombolytic activity, modulate
 CC inflammation, cancers, cardiovascular disorders, neurological disease and
 CC bacterial or viral infections. The peptides, nucleotides, antibodies,
 CC agonists and antagonists may be also be used in drug screens. AAC78449 to
 CC AAC78457 and AAB44240 represent sequences used in the exemplification of
 CC the present invention.
 XX
 SQ Sequence 302 AA:
 Query Match 22.1%; Score 318; DB 21; Length 302;
 Best Local Similarity 35.3%; Pred. No. 1.8e-21;
 Matches 83; Conservative 31; Mismatches 79; Indels 42; Gaps 12;
 QY 2 KOILPALETTA-NLIFPLLELVAGLSPFANEKDPATFALLTOTOVOEYIKRN 60
 DB 34 ROSKRYLATIAMNSFVSNSTRNLDPD-ENED------FIKCYRIRN 78
 QY 61 ELRRVSPPARNMLKEMNKKAANOKNANOCNHRHS---NPKDRM---TSLKCGENL 113
 DB 79 KFESEVPTASDMLWTMPALQAKAMSNOCFSHNRRLKPPKRLHPNTSL--GEPI 136
 QY 114 YMSAP-SSWSQAIOSEMFDEYNDFGVGPKTPNAVGHYTYOVVSYLVGCGNAYCPN 172
 DB 137 WTGSVPFISVSAITWYDEIDODFT--RICKKVCGHYQVWVADSYKVCAGVQFCP- 193
 QY 173 OKVLKY-----YVCGCPCPAGMANRLVPEEGAPCASCPCPN--CDGCLCTN 218
 DB 194 -KVGFDALNSGAHFICNIGPGNIPTR--WPKKCATXSACPNKCLDNLZCVN 244

RESULT 14
 AAB64952
 ID AAB64952 standard; Protein: 181 AA.
 XX
 AC AAB64952;
 XX
 DT 23-MAR-2001 (first entry)
 XX
 DE Gene 12 human secreted protein homologous amino acid sequence #130.
 XX
 KW Human; secreted protein; diagnosis; immunomodulatory; antisclerotic;
 KW dermatological; immunosuppressive; antinflammatory; anti-HIV;
 KW immunostimulant; cytostatic; cardiant; vascular; anti-angiogenic;
 KW ophthalmological; neuroprotectant; neoplastic; anticonvulsant; vulnerary;
 KW antiallergic; antiparasitic; antiparasitic; immune disorder;
 KW multiple sclerosis; systemic lupus erythematosus; HIV; infection;
 KW hyperproliferative disorder; cancer; Gaucher's disease; wound healing;
 KW cardiovascular disease; Schmitz syndrome; Chaga's cardiomyopathy;
 KW coronary arteriosclerosis; angiotensin disorder; diabetic retinopathy;
 KW corneal graft neovascularisation; neurological disorder; regeneration;
 KW Huntington's chorea; Alzheimer's disease; Parkinson's disease;
 KW infectious disease; chemotaxis.

OS Homo sapiens.
 XX
 PN WO200076530-A1.
 XX
 PD 21-DEC-2000.
 XX
 PE 01-JUN-2000; 2000WO-US14933.
 XX
 PR 11-JUN-1999; 99US-0138572.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI (ROSE/) ROSEN C A.
 XX
 DR Rosen CA, Ruben SM, Komatsoulis GA;
 XX
 PT Nucleic acids encoding 49 human secreted polypeptides, useful for
 PT preventing, diagnosing and/or treating e.g. cancers, Parkinson's
 PT disease and diabetic retinopathy -
 XX
 PS Disclosure: Page 528-529; 554pp; English.
 XX
 CC The polynucleotide sequences given in AAF33213 to AAF33261 encode the
 CC human secreted proteins given in AAB64882 to AAB64930. AAB64931 to
 CC AAB64991 represent human secreted polypeptide sequences and proteins
 CC homologous to them, which are given in the exemplification of the present
 CC invention. Human secreted proteins have activities based on the tissues
 CC and cells the genes are expressed in. Examples of activities include:
 CC immunomodulatory; anti-HIV; immunostimulant; immunosuppressive;
 CC antinflammatory; anti-sclerotic; dermatological; cytostatic; cardiant;
 CC vascular; antidiabetic; antihypertensive; ophthalmological;
 CC neuroprotectant; anticonvulsant; neoplastic; antiallergic;
 CC antiparasitic; antiparasitic; antiparasitic; antiparasitic;
 CC antiparasitic; antiparasitic; antiparasitic; antiparasitic;
 CC be used in the prevention, diagnosis and treatment of diseases associated
 CC with inappropriate polypeptide expression. Disorders that may be
 CC prevented, diagnosed and/or treated by the above methods include immune
 CC disorders (e.g. multiple sclerosis, systemic lupus erythematosus and
 CC human immunodeficiency virus (HIV) infections), hyperproliferative
 CC disorders (e.g. cancers and Gaucher's disease), cardiovascular diseases
 CC (e.g. Schmitz syndrome, Chaga's cardiomyopathy and coronary
 CC arteriosclerosis), angiotensin disorder (e.g. corneal graft
 CC neovascularisation), angiotensin disorder (e.g. corneal graft
 CC (e.g. Huntington's chorea, Alzheimer's disease and Parkinson's disease),
 CC infectious diseases and/or for promoting wound healing, regeneration and
 CC /or chemotaxis. AAF33204 to AAF33212 and AAB64881 represent sequences
 CC used in the exemplification of the present invention.
 XX
 SQ Sequence 181 AA:
 Query Match 21.9%; Score 315; DB 22; Length 181;
 Best Local Similarity 38.7%; Pred. No. 1.8e-21;
 Matches 70; Conservative 29; Mismatches 56; Indels 26; Gaps 9;
 QY 53 REIVKHNELRAVSPPARNMLKEMNKKAANOKNANOCNHRHS---NPKDRM---T 105
 DB 10 KDCVRIHNKFESEVPTASDMLWTMPALQAKAMSNOCFSHNRRLKPPKRLHPNTSL 69
 QY 106 SLKCGENLYMSAP-SSWSQAIOSEMFDEYNDFGVGPKTPNAVGHYTYOVVSYLVG 164
 DB 70 SL--GENIWTGSVPFISVSAITWYDEIDODFT--RICKKVCGHYQVWVADSYKVC 125
 QY 165 CGNAYCPNOKVLKY-----YVCGCPCPAGMANRLVPEEGAPCASCPCPN--CDGCL 215
 DB 126 CAVQFCP--KVGFDALNSGAHFICNIGPGNIPTR--WPKKCATXSACPNKCLDNL 180
 QY 216 C 216
 DB 181 C 181

RESULT 15
 AAE21099

ID	AAE21099 standard; Protein: 162 AA.
XX	AAE21099;
AC	
XX	
DT	01-JUL-2002 (first entry)
DE	Human sperm-coating protein (SCP)-like domain consensus sequence.
KM	Human; haematopoiesis; clotting; kidney failure; wound healing; cancer;
KM	neoplasia; pancreatic disorder; pancreatitis; cerebrovascular disease;
KM	heart disorder; ischemic heart disease; neuroprotective; vulnery;
KM	cardiovascular disorder; ischemic heart disease; immunosuppressive;
KM	glomerular disease; glomerulonephritis; uterine disorder; hyperplasia;
KM	fetal spleen; prostate disorder; inflammatory disease; Crohn's disease;
KM	proliferative disorder; gynaecological; haemostatic; antibacterial;
KM	systemic lupus erythematosus; immunodeficiency disorder; antiasthmatic;
KM	cystostatic; nephrotoxic; antidiabetic; cerebroprotective; traumatic;
KM	hypertensive; tumour; injury; trauma; antiangiial; vasotropic; anticancer;
KM	apoptotic disorder; rheumatoid arthritis; cardiac; renal disorder;
KM	hepatotropic; antipsoriatic; antiallergic; dermatological; virucide;
KM	sperm-coating protein; SCP.
OS	
XX	Homo sapiens.
XX	
PN	US2002028508-A1.
PD	
XX	07-MAR-2002.
FE	21-FEB-2001; 2001US-0790264.
XX	
PR	23-APR-1998; 98US-0065363.
PR	23-APR-1998; 98US-0065661.
PR	22-JUN-1998; 98US-0102705.
PR	29-JUL-1998; 98US-0124538.
PR	23-APR-1999; 99US-0298531.
PR	22-JUN-1999; 99US-037930.
XX	29-JUL-1999; 99US-0363630.
PA	(HOLT/) HOLTMAN D A.
PA	(GOOD/) GOODEARTI A D J.
PA	(MCCA/) MCCARTHY S A.
PI	
DR	Holtzman DA, Goodearti ADJ, McCarthy SA.
XX	
WP	WPI: 2002-303420/34.
PT	
PT	Novel TANGO polypeptides and nucleic acid molecules useful as
PT	modulating agents in regulating cellular processes and for diagnosing
PT	and treating heart, liver, lung, kidney, inflammatory and cellular
PT	proliferative disorders
XX	
PS	
XX	Example 3; Fig 2A; 138pp; English.
CC	The invention relates to nucleic acids encoding a variety of proteins
CC	human T139 (TANGO-139), T125 (TANGO-125), T110 (TANGO-110), murine T175
CC	(TANGO-175), human T175 or murine WDM-2, having diagnostic, preventive,
CC	therapeutic and other uses. Polypeptide of the invention has the ability
CC	to inhibit a proteinase activity, to modulate cell-cell interactions,
CC	haematopoiesis and the ability to modulate clotting. Polypeptide and
CC	polynucleotide of the invention are useful for diagnosing and treating
CC	disorder characterised by their aberrant expression or activity. The
CC	antibodies are useful as modulating agents in regulating a variety of
CC	cellular processes e.g. cell proliferation and/or cell differentiation.
CC	TANGO-139 is useful for treating kidney defects such as kidney failure,
CC	TANGO-125 is useful in wound healing and for treating cancer. TANGO-110
CC	is useful for treating neoplasia. TANGO-177 or WDM-2 is useful for
CC	treating cancer. are useful to treat pancreatic disorders, such as
CC	pancreatitis, cerebrovascular disease, and tumours, and injury or trauma
CC	to the brain. TANGO-125, 110, 175 molecules treat heart disorders, e.g.,
CC	ischemic heart disease, cardiovascular disorders, such as ischemic
CC	heart disease. TANGO-139, 125, 110 and 175 molecules are useful to treat
CC	renal (kidney) disorders, such as glomerular disease (e.g., acute and
CC	chronic glomerulonephritis), TANGO-175 is useful to treat uterine

```

CC disorders, hyperplasia of the endometrium. TANGO-110 is useful to treat
CC spleen, e.g., the fetal spleen, associated diseases and disorder. TANGO-
CC 125 treats prostate disorders, such as inflammatory diseases, Crohn's
CC disease and tumours. TANGO-119, 125, 110, 175 or MDNW-2 are useful for
CC treating proliferative disorders, inflammatory disorders. TANGO-175, or
CC MDNW-2 activity also include apoptotic disorders, rheumatoid arthritis,
CC systemic lupus erythematosus, insulin-dependent diabetes mellitus,
CC immune-related disorders, e.g., immunodeficiency disorders, viral
CC disorders, cell growth disorders, e.g., cancers and inflammatory
CC disorders and apoptotic disorders. The nucleic acids of the invention
CC are used in gene therapy. The present sequence is human sperm-coating
CC protein (SCP)-like domain consensus sequence related to human TANGO
CC protein.
CC
CC
xx
SQ Sequence 162 AA:
21.18: Score 303; DB 23; Length 162;
Query Match Best Local Similarity 39.18; Pred. No. 2e+20; 53; Indels 20; Gaps
Matches 63; Conservative 25; Mismatches 53;
QY 52 QRELYVKNHNELEPRAY-----SPARRNLKMKENKEEPAANAKQANOCNTRSHN 99
DQ 2 QDEILNKNHNFQVGGLETRGCRNGPGRPPAPSNPNPNVWDELADIAONANOCITDHDH 61
QY 100 PDRMTSLKGCENT--YVSSAPF--SMSAOLDSMFDEYNDPFGVGPATPR--AAVGHY 152
DB 62 CCRNHSKRYQYGGORIMAMSSSTANNVNMNMSIMIDQYNYENVKDKYNNNTGCGGNPNFVCGHY 121
QY 153 TQVWYSSYLVCQGNAYC-PQKYLKYUUYUQCPAPNMAN 192
DB 122 TQWVWNTPELGGASISLCYCANNHKKHYUUYVCYPCRRNYNN 162

```